Inclusion Criteria:

- Patients with acute myeloid leukemia that progressed or relapsed after two regimens
of therapy. Patients must not have received radiotherapy, chemotherapy (with the
exception of hydroxyurea which must be discontinued 72 hours prior to therapy) or
biological therapy within the preceding 2 weeks and must have recovered from any
adverse events due to prior administered agents

- Assessable disease as measured by laboratory and bone marrow examinations

- Age: Eighteen years or older

- Performance status: ECOG ≤ 2 (Appendix A)

- Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥ 50 mL/min
(using the Cockcroft-Gault equation CL creatinine = ((140-age) x body mass X 0.85 if
female)/72 x creatinine where age is given in years,body mass is given in Kg and
creatinine is given in mg/dL)

- Aspartate aminotransferase (AST) ≤ 59 IU/L

- Alanine aminotransferase (ALT) ≤ 72 IU/L

- Total bilirubin ≤ 1.3 mg/ml

- Patients must have left ventricular ejection fraction (LVEF) ≥50 %

- Females of child-bearing potential must have a negative pregnancy test and all
subjects must agree to use an effective method of contraception

- Ability to give informed consent

- Life expectancy of greater than 3 months Note: as many of eligible patients will be
pancytopenic secondary to their disease, hematologic abnormalities we will not be
used as a criteria for entry or exclusion.

Exclusion Criteria:

- Patients with acute promyelocytic leukemia

- Symptomatic central nervous system (CNS) involvement

- History of congestive heart failure

- Myocardial infarction in the past 6 months

- Uncontrolled, life-threatening infection that is not responding to antimicrobial
therapy

- Concurrent treatment with corticosteroids and/or other immunosuppressive drugs

- ECOG performance status >2 (Appendix A)

- Hepatitis B or C or HIV positive serology

- History of psychiatric disorder which may compromise compliance with the protocol or
which does not allow for appropriate informed consent

- Patient may not be receiving any other investigational agents

- PT INR> 1.5 or patient is receiving systemic anticoagulation (e.g., warfarin)

- Patient undergone autologous or allogeneic stem cell transplantation

- History of another primary cancer except for curatively treated in situ cervical
cancer and curatively resected non-melanoma skin cancer